

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
18 January 2024 (18.01.2024)



(10) International Publication Number
WO 2024/015717 A3

(51) International Patent Classification:

A61K 31/167 (2006.01) *A61P 11/00* (2006.01)
A61K 31/4375 (2006.01) *C07D 239/94* (2006.01)
A61K 31/517 (2006.01) *C07D 471/04* (2006.01)

63/463,006

29 April 2023 (29.04.2023)

US

(71) Applicant: **PLIANT THERAPEUTICS, INC.** [US/US];
260 Littlefield Avenue, South San Francisco, California
94080 (US).

(21) International Application Number:

PCT/US2023/069826

(72) Inventors; and

(71) Applicants: **LEFEBVRE, Eric** [CA/US]; c/o Pliant Therapeutics, Inc., 260 Littlefield Avenue, South San Francisco, California 94080 (US). **COSGROVE, Gregory P.** [US/US]; c/o Pliant Therapeutics, Inc., 260 Littlefield Avenue, South San Francisco, California 94080 (US). **TURNER, Scott** [US/US]; c/o Pliant Therapeutics, Inc., 260 Littlefield Avenue, South San Francisco, California 94080 (US). **DECARIS, Martin L.** [US/US]; c/o Pliant Therapeutics, Inc., 260 Littlefield Avenue, South San Francisco, California 94080 (US). **SCHAUB, Johanna Roberta** [US/US];

(22) International Filing Date:

07 July 2023 (07.07.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/359,835	09 July 2022 (09.07.2022)	US
63/359,875	10 July 2022 (10.07.2022)	US
63/416,453	14 October 2022 (14.10.2022)	US
63/440,406	21 January 2023 (21.01.2023)	US

(54) Title: INTEGRIN INHIBITORS AND USES THEREOF IN COMBINATION WITH OTHER AGENTS




FIG. 31

(57) Abstract: The invention relates to methods of (i) treating a subject for a disease, (ii) amelioration of decline of forced vital capacity in a subject in need thereof, (iii) modulating avf36 integrin, avf31 integrin, or both avf36 integrin and avf31 integrin in a subject in need thereof, (iv) increasing the expression of one or more genes in a subject in need thereof, (v) decreasing the expression of one or more genes in a subject in need thereof, and (vi) modulating the activity of at least one gene affecting fibrotic activity in a subject in need thereof, comprising administration of compounds of Formula (A), Formula (I), Formula (II), or (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)amino)-2-(quinazolin-4-ylamino)butanoic acid, or a pharmaceutically acceptable salt thereof as described herein; and administering to the subject at least a second drug selected from pirfenidone and nintedanib, or a salt thereof.

[Continued on next page]

c/o Pliant Therapeutics, Inc., 260 Littlefield Avenue, South
San Francisco, California 94080 (US).

(74) **Agent: CERPA, Robert et al.;** Morrison & Foerster LLP,
755 Page Mill Road, Palo Alto, California 94304-1018
(US).

(81) **Designated States** (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(88) **Date of publication of the international search report:**
04 April 2024 (04.04.2024)